Due to high demand, this product is limited to 20 per organization per 60 days.
This isolate is lineage B.1.1.7, clade GR according to GISAID (Global Initiative on Sharing All Influenza Data) conventions.
The following mutations were identified in the clinical isolate: Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del, M (Membrane protein) V70L, N (Nucleocapsid protein) D3L, N G204R, N R203K, N S235F, NS3 T223I, NS8 (Non-structural protein 8) Q27stop, NS8 R52I, NS8 Y73C, NSP3 (Non-structural protein 3) A890D, NSP3 I1412T, NSP3 T183I, NSP6 (Non-structural protein 6) F108del, NSP6 G107del, NSP6 S106del, NSP12 (Non-structural protein 12) P323L, NSP13 (Non-structural protein 13) A454V, NSP13 K460R.
One additional SNP in ORF1ab L3826F was reported in the deposited passage two virus, in comparison to the clinical specimen.
Each vial contains approximately 0.25 mL of heat-inactivated, clarified cell lysate and supernatant from Vero cells infected with SARS-CoV-2 strain USA/CA_CDC_5574/2020. The vial should be centrifuged prior to opening.
The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt.